CLINDAMYCIN PHOSPHATE VAGINAL CREAM USP, 2%

Manufacturer
Physicians Total Care, Inc.
Effective date
2009-08-31
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:10:15

Label at a glance#

ProductClindamycin Phosphate
Active ingredientCLINDAMYCIN PHOSPHATE
Label structure16 sections

Indications and uses

Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES. ) NOTE: For purpo...

Dosage and administration

The recommended dose is one applicatorful of clindamycin phosphate vaginal cream 2%, (5 grams containing approximately 100 mg of clindamycin phosphate) intravaginally, preferably at bedtime, for 3 or 7 consecutive days in non-pregnant patients and for 7 consecutive days in pregnant patients. (See CLINICAL STUDIES. )

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

FOR INTRAVAGINAL USE ONLY
NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE

DESCRIPTION

DESCRIPTION SECTION

Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl- trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate). It has a molecular weight of 504.96, and the molecular formula is C18H34ClN2O8 PS. The structural formula is represented below:

Structural Formula
Structural Formula

Clindamycin phosphate vaginal cream 2%, is a semi-solid, white cream, which contains 2% clindamycin phosphate, USP, at a concentration equivalent to 20 mg clindamycin per gram. The pH of the cream is between 3.0 and 6.0. The cream also contains benzyl alcohol, cetostearyl alcohol, cetyl palmitate, mineral oil, polysorbate 60, propylene glycol, sorbitan monostearate, and stearic acid.

Each applicatorful of 5 grams of vaginal cream contains approximately 100 mg of clindamycin phosphate.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Following a once a day intravaginal dose of 100 mg of clindamycin phosphate vaginal cream 2%, administered to 6 healthy female volunteers for 7 days, approximately 5% (range 0.6% to 11%) of the administered dose was absorbed systemically. The peak serum clindamycin concentration observed on the first day averaged 18 ng/mL (range 4 to 47 ng/mL) and on day 7 it averaged 25 ng/mL (range 6 to 61 ng/mL). These peak concentrations were attained approximately 10 hours post-dosing (range 4-24 hours).

Following a once a day intravaginal dose of 100 mg of clindamycin phosphate vaginal cream 2%, administered for 7 consecutive days to 5 women with bacterial vaginosis, absorption was slower and less variable than that observed in healthy females. Approximately 5% (range 2% to 8%) of the dose was absorbed systemically. The peak serum clindamycin concentration observed on the first day averaged 13 ng/mL (range 6 to 34 ng/mL) and on day 7 it averaged 16 ng/mL (range 7 to 26 ng/mL). These peak concentrations were attained approximately 14 hours post-dosing (range 4-24 hours).

There was little or no systemic accumulation of clindamycin after repeated vaginal dosing of clindamycin phosphate vaginal cream 2%. The systemic half-life was 1.5 to 2.6 hours.

MICROBIOLOGY

SPL UNCLASSIFIED SECTION

Clindamycin inhibits bacterial protein synthesis at the level of the bacterial ribosome. The antibiotic binds preferentially to the 50S ribosomal subunit and affects the process of peptide chain initiation. Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.

Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of bacterial vaginosis. (See INDICATIONS AND USAGE.) Standard methodology for the susceptibility testing of the potential bacterial vaginosis pathogens, Gardnerella vaginalis, Mobiluncus spp., or Mycoplasma hominis, has not been defined. Nonetheless, clindamycin is an antimicrobial agent active in vitro against most strains of the following organisms that have been reported to be associated with bacterial vaginosis:

Bacteroides spp.Mycoplasma hominis
Peptostreptococcus spp.Gardnerella vaginalis
Mobiluncus spp.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES.)

NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells.

Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus should be ruled out.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Clindamycin phosphate vaginal cream 2%, is contraindicated in individuals with a history of hypersensitivity to clindamycin, lincomycin, or any of the components of this vaginal cream. Clindamycin phosphate vaginal cream 2%, is also contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or a history of "antibiotic-associated" colitis.

WARNINGS

WARNINGS SECTION

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of orally and parenterally administered clindamycin, as well as with topical (dermal) formulations of clindamycin. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of clindamycin, even when administered by the vaginal route, because approximately 5% of the clindamycin dose is systemically absorbed from the vagina.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of "antibiotic-associated′′ colitis.

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against Clostridium difficile colitis.

Onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Clindamycin phosphate vaginal cream 2%, contains ingredients that will cause burning and irritation of the eye. In the event of accidental contact with the eye, rinse the eye with copious amounts of cool tap water.

The use of clindamycin phosphate vaginal cream 2% may result in the overgrowth of nonsusceptible organisms in the vagina. In clinical studies involving 600 non-pregnant women who received treatment for 3 days, Candida albicans was detected, either symptomatically or by culture, in 8.8% of patients. In 9% of the patients, vaginitis was recorded. In clinical studies involving 1325 non-pregnant women who received treatment for 7 days, Candida albicans was detected, either symptomatically or by culture, in 10.5% of patients. Vaginitis was recorded in 10.7% of the patients. In 180 pregnant women who received treatment for 7 days, Candida albicans was detected, either symptomatically or by culture, in 13.3% of patients. In 7.2% of the patients, vaginitis was recorded. Candida albicans, as reported here, includes the terms: vaginal moniliasis and moniliasis (body as a whole). Vaginitis includes the terms: vulvo-vaginal disorder, vulvovaginitis, vaginal discharge, trichomonal vaginitis, and vaginitis.

Information for the Patient:

INFORMATION FOR PATIENTS SECTION

The patient should be instructed not to engage in vaginal intercourse, or use other vaginal products (such as tampons or douches) during treatment with this product.

The patient should also be advised that this cream contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, use of such products within 72 hours following treatment with clindamycin phosphate vaginal cream 2%, is not recommended.

Drug Interactions

DRUG INTERACTIONS SECTION

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames test. Both tests were negative. Fertility studies in rats treated orally with up to 300 mg/kg/day (31 times the human exposure based on mg/m2 ) revealed no effects on fertility or mating ability.

Pregnancy: Teratogenic effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category B

SPL UNCLASSIFIED SECTION

There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. This drug should be used during the first trimester of pregnancy only if clearly needed.

Clindamycin phosphate vaginal cream 2% has been studied in pregnant women during the second trimester. In women treated for seven days, abnormal labor was reported in 1.1% of patients who received clindamycin vaginal cream 2% compared with 0.5% of patients who received placebo.

Reproduction studies have been performed in rats and mice using oral and parenteral doses of clindamycin up to 600 mg/kg/day (62 and 25 times, respectively, the maximum human exposure based on mg/m2 ) and have revealed no evidence of harm to the fetus due to clindamycin. In one mouse strain, cleft palates were observed in treated fetuses; this outcome was not produced in other mouse strains or in other species and is, therefore, considered to be a strain specific effect.

See INDICATIONS AND USAGE; PRECAUTIONS, General; and ADVERSE REACTIONS.

Nursing Mothers

NURSING MOTHERS SECTION

Clindamycin has been detected in human milk after oral or parenteral administration. It is not known if clindamycin is excreted in human milk following the use of vaginally administered clindamycin phosphate.

Because of the potential for serious adverse reactions in nursing infants from clindamycin phosphate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use:

GERIATRIC USE SECTION

Clinical studies for clindamycin phosphate vaginal cream 2% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Clinical trials

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

Non-pregnant Women: In clinical trials involving non-pregnant women, 1.8% of 600 patients who received treatment with clindamycin phosphate vaginal cream 2% for 3 days and 2.7% of 1325 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered clindamycin phosphate vaginal cream 2%, were reported for 20.7% of the patients receiving treatment for 3 days and 21.3% of the patients receiving treatment for 7 days. Events occurring in ≥1% of patients receiving clindamycin phosphate vaginal cream 2% are shown in Table 1.

Events Occuring in ≥ 1% of Non-pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2%
Events Occuring in ≥ 1% of Non-pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2%

Other events occurring in <1% of the clindamycin vaginal cream 2% groups include:

Urogenital system: vaginal discharge, metrorrhagia, urinary tract infection, endometriosis, menstrual disorder, vaginitis/vaginal infection, and vaginal pain.

Body as a whole: localized abdominal pain, generalized abdominal pain, abdominal cramps, halitosis, headache, bacterial infection, inflammatory swelling, allergic reaction, and fungal infection.

Digestive system: nausea, vomiting, constipation, dyspepsia, flatulence, diarrhea, and gastrointestinal disorder.

Endocrine system: hyperthyroidism.

Central nervous system: dizziness and vertigo.

Respiratory system: epistaxis.

Skin: pruritus (non-application site), moniliasis, rash, maculopapular rash, erythema, and urticaria.

Special senses: taste perversion.

SPL UNCLASSIFIED SECTION

Pregnant Women: In a clinical trial involving pregnant women during the second trimester, 1.7% of 180 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered clindamycin phosphate vaginal cream 2%, were reported for 22.8% of pregnant patients. Events occurring in ≥1% of patients receiving either clindamycin phosphate vaginal cream 2% or placebo are shown in Table 2.

Events Occuring in ≥ 1% of Pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2% or Placebo
Events Occuring in ≥ 1% of Pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2% or Placebo

Other events occurring in <1% of the clindamycin vaginal cream 2% group include:

Urogenital system: dysuria, metrorrhagia, vaginal pain, and trichomonal vaginitis.

Body as a whole: upper respiratory infection.

Skin: pruritus (topical application site) and erythema.

Other clindamycin formulations:

SPL UNCLASSIFIED SECTION

Clindamycin vaginal cream affords minimal peak serum levels and systemic exposure (AUCs) of clindamycin compared to 100 mg oral clindamycin dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral clindamycin, the possibility of these and other reactions cannot be excluded presently. Data from well-controlled trials directly comparing clindamycin administered orally to clindamycin administered vaginally are not available.

SPL UNCLASSIFIED SECTION

The following adverse reactions and altered laboratory tests have been reported with the oral or parenteral use of clindamycin:

Gastrointestinal: Abdominal pain, esophagitis, nausea, vomiting, and diarrhea. (See WARNINGS.)

Hematopoietic: Transient neutropenia (leukopenia), eosinophilia, agranulocytosis, and thrombocytopenia have been reported. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of these reports.

Hypersensitivity Reactions: Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. A few cases of anaphylactoid reactions have been reported. If a hypersensitivity reaction occurs, the drug should be discontinued.

Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.

Musculoskeletal: Rare instances of polyarthritis have been reported.

Renal: Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances.

OVERDOSAGE

OVERDOSAGE SECTION

Vaginally applied clindamycin phosphate vaginal cream 2% could be absorbed in sufficient amounts to produce systemic effects. (See WARNINGS.)

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dose is one applicatorful of clindamycin phosphate vaginal cream 2%, (5 grams containing approximately 100 mg of clindamycin phosphate) intravaginally, preferably at bedtime, for 3 or 7 consecutive days in non-pregnant patients and for 7 consecutive days in pregnant patients. (See CLINICAL STUDIES.)

HOW SUPPLIED

HOW SUPPLIED SECTION

Clindamycin Phosphate Vaginal Cream 2% (clindamycin phosphate vaginal cream) is a white to off-white cream having a slight odor and is supplied as follows:

40 g tube (with 7 disposable applicators)  NDC 54868-5307-0

Store at 20° to 25°C (68° to 77° F)[see USP Controlled Room Temperature].

CLINICAL STUDIES

CLINICAL STUDIES SECTION

In two clinical studies involving 674 evaluable non-pregnant women with bacterial vaginosis comparing clindamycin phosphate vaginal cream 2% for 3 or 7 days, the clinical cure rates, determined at 1 month posttherapy, ranged from 72% to 81% for the 3-day treatment and 84% to 86% for the 7-day treatment.


Clindamycin Phosphate 3 DayClindamycin Phosphate 7 Day
U.S. Study94/13172%110/12886%
European Study161/19981%181/21684%

In a clinical study involving 249 evaluable pregnant patients in the second and third trimester treated for 7 days, the clinical cure rate, determined at 1 month posttherapy, was 60% (77/129) in the clindamycin arm and 9% (11/120) for the vehicle arm. The determination of clinical cure was based on the absence of a "fishy" amine odor when the vaginal discharge was mixed with a 10% KOH solution and the absence of clue cells on microscopic examination.

E. FOUGERA & CO.
A division of Nycomed US Inc.
Melville, New York 11747

I2277
R4/08
#116


Relabeling of "Additional Barcode Label" by:
Physicians Total Care, Inc.
Tulsa, OK      74146

DIRECTIONS FOR USE

SPL PATIENT PACKAGE INSERT SECTION

7 Disposable plastic applicators are provided with this package. They are designed to allow proper vaginal administration of the cream.

Remove cap from cream tube. Screw a plastic applicator on the threaded end of the tube.

Rolling tube from the bottom, squeeze gently and force the medication into the applicator.

The applicator is filled when the plunger reaches its predetermined stopping point.

Unscrew the applicator from the tube and replace the cap.

Figure
Figure

While lying on your back, firmly grasp the applicator barrel and insert into vagina as far as possible without causing discomfort.

Slowly push the plunger until it stops. Carefully withdraw applicator from vagina, and discard applicator.

Figure
Figure

REMEMBER TO APPLY ONE APPLICATORFUL EACH NIGHT BEFORE BEDTIME, OR AS PRESCRIBED BY YOUR DOCTOR.

INSTRUCCIONES PARA LA PACIENTE

SPL PATIENT PACKAGE INSERT SECTION

Este envase contiene 7 aplicadores de plástico desechables. Los aplicadores están diseñados para la adminstración apropiada de la crema en la vagina.

Remueva la tapa del tubo de crema y enrosque el aplicador de plástico al tubo.

Exprima el tubo suavemente desde el extremo inferior y fuerce el medicamento al aplicador.

El aplicador estará lleno cuando el émbolo llega a su máxima longitud. Desenrosque el aplicador del tubo y vuelva a poner la tapa.

Figure
Figure

Acuéstese de espada y agarrando firemente el aplicador, introdúzcalo en la vagina tanto como sea posible sin causar molestias.

Empuje lentamente el émbolo hasta que se detenga.

Saque el aplicador cuidadosamente de la vagina y descártelo.

Figure
Figure

RECUERDE APLICARSE UN APLICADOR LLENO TODAS LAS NOCHES AL ACOSTARSE, O DE ACUDERDO CON LAS INDICACIONES DE SU MEDICO.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 40 GRAM CARTON

CLINDAMYCIN
PHOSPHATE
VAGINAL CREAM
USP, 2%
equivalent to 2% clindamycin

For Intravaginal Use Only.
Not for Ophthalmic,
Dermal, or Oral Use.

Rx only

NET WT 40 grams
with
7 applicators

40 GRAM CARTON40 GRAM CARTON

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309337clindamycin phosphate 2 % Vaginal CreamPSN1
309337clindamycin 20 MG/ML Vaginal CreamSCD1
309337clindamycin (as clindamycin phosphate) 2 % Vaginal CreamSY1
309337clindamycin 2 % Vaginal CreamSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CLINDAMYCIN Pharmacologic Class Indexing3Indexing - Pharmacologic Class20210811

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a46239a7-5963-4008-8cbb-6b9000f497ebProduct name120250721
1426d8f8-b7d5-4053-8554-613df00c0d86Product name220250616
b382b4e1-6b48-45f6-bffc-e61b00b0ce19Product name320250317
d8f81258-db12-0761-46cc-8ff6e62e9302Product name420240422
b7b2fa42-1c77-d724-81f0-87da60a77e79Product name320240320
b27c7c65-51f2-a62f-e0e6-a26b3a0f8eb0Product name320230425
e3af9708-3004-7392-4046-5311eaa8bab5Product name320221128
ffb4bacf-f636-0f7d-0b0d-7a4b151243e3Product name920220928
b72227d6-0388-43bd-995b-b762d2754cd5Product name120220706
a92d22e0-3af4-f301-bc88-27ff030b0070Product name220220316
4a7d44fe-774d-404b-aad0-8a90fe78375aProduct name420211025
d12e2d7c-bd6b-45d4-94f9-6df8e1b8b27bProduct name320200203
ee5c6de5-d9cd-454f-b250-7b19e5cf2992Product name420190619
5ce6ce33-4f2b-3ce0-757d-e520013280cfProduct name520180719
b92a26f1-6926-4817-be73-e26ab4c2146fProduct name120170602
028d6c95-5012-6976-2075-dee0ae6fefe2Product name120140508
468b2c08-8adb-8d0f-8257-c6515a061424Product name120140508
8959fb29-d86f-c521-666a-b4cb22233594Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
54868-5307-02019-09-24C16284748780-19350213a-4109-c013-e053-90daa90a1393CLINDAMYCIN PHOSPHATE VAGINAL CREAM USP, 2%

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-5307-0Clindamycin Phosphate1 in 1 CARTONCREAM11
54868-5307-0Clindamycin Phosphate40 g in 1 TUBE, WITH APPLICATORCREAM401

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-5307CLINDAMYCIN PHOSPHATE CREAM [PHYSICIANS TOTAL CARE, INC.]12 package rows20101021_706dd0b6-367c-4950-88fe-7a6c0661c2b9.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0168-0277-40GM - Gram0168-0277767920be-c20c-4254-9fcb-51826529495412012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CLINDAMYCIN PHOSPHATEACTIVE INGREDIENTEH6D7113I81
CLINDAMYCINACTIVE MOIETY3U02EL437C1
BENZYL ALCOHOLINACTIVE INGREDIENTLKG8494WBH1
CETOSTEARYL ALCOHOLINACTIVE INGREDIENT2DMT128M1S1
CETYL PALMITATEINACTIVE INGREDIENT5ZA2S6B08X1
MINERAL OILINACTIVE INGREDIENTT5L8T28FGP1
POLYSORBATE 60INACTIVE INGREDIENTCAL22UVI4M1
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V31
SORBITAN MONOSTEARATEINACTIVE INGREDIENTNVZ4I0H58X1
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65AP1
WATERINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-530754868-5307-0
0168-0277

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 8 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
CETOSTEARYL ALCOHOLCETOSTEARYL ALCOHOL2DMT128M1SCREAM / VAGINAL6 mgExact identifier — unii+route+dosage form
CETYL PALMITATECETYL PALMITATE5ZA2S6B08XCREAM / VAGINAL165 mgExact identifier — unii+route+dosage form
POLYSORBATE 60POLYSORBATE 60CAL22UVI4MCREAM / VAGINAL200 mgExact identifier — unii+route+dosage form
STEARIC ACIDSTEARIC ACID4ELV7Z65APCREAM / VAGINAL1088 mgExact identifier — unii+route+dosage form
MINERAL OILMINERAL OILT5L8T28FGPCREAM / VAGINAL402 mgExact identifier — unii+route+dosage form
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CREAM / VAGINAL1225 mgExact identifier — unii+route+dosage form
SORBITAN MONOSTEARATESORBITAN MONOSTEARATENVZ4I0H58XCREAM / VAGINAL100 mgExact identifier — unii+route+dosage form
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHCREAM / VAGINAL1 %w/wExact identifier — unii+route+dosage form

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A065139-001CLINDAMYCIN PHOSPHATECLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALABRS2004-12-27

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A065139-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALABRS2004-12-27d4dbc9d85df4…
2026-10-15 13:18:302026-09A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALABRS2004-12-27c2088c7a36db…
2026-09-14 22:38:342026-08A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALABRS2004-12-2784e616aacf4f…
2026-08-18 06:07:402026-07A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-2731067a03dcf5…
2025-08-23 18:47 UTC2025-08A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-276a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-2703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-272680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-275bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-2779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-271e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-278072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-275c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-275d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-274b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-2774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-2787673890dc5c…
2021-03-12 10:30 UTC2021-03A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-275aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-278869cabd3fbd…
2020-11-12 02:37 UTC2020-11A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27c0c555d07b60…
2019-12-14 00:12 UTC2019-12A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-273f01610625f2…
2019-09-15 20:21 UTC2019-09A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27b00525d2431f…
2019-07-19 19:46 UTC2019-07A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-276a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-271c564ffb4f44…
2023-12-20 04:57 UTC2023-12A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-279b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-273f0d92c62455…
2023-05-13 08:27 UTC2023-05A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-27053a50430f4f…
2023-01-26 05:58 UTC2023-01A065139-001CLINDAMYCIN PHOSPHATEEQ 2% BASECREAM / VAGINALAB2004-12-273bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A065139-001AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A065139-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A065139-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A065139-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A065139-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A065139-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A065139-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A065139-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A065139-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A065139-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A065139-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A065139-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A065139-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A065139-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A065139-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A065139-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A065139-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A065139-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A065139-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A065139-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A065139-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A065139-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A065139-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A065139-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A065139-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A065139-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A065139-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A065139-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A065139-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A065139-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A065139-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A065139-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A065139-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A065139-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A065139-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A065139-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A065139-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A065139-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A065139-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A065139-001AB13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Clindamycin PhosphateCLINDAMYCIN PHOSPHATEE. Fougera & Co. a division of Fougera Pharmaceuticals, LLC997a23c8-f0d7-49d5-af33-e11f2ddab3c72026-01-28Warnings, Adverse reactionsExact identifier
ndc (product): 0168-0277
580d387f-c4ba-4a04-b664-8b93aa6fe483706dd0b6-367c-4950-88fe-7a6c0661c2b92009-08-31Warnings, Adverse reactionsExact identifier
spl id: 580d387f-c4ba-4a04-b664-8b93aa6fe483
spl set id: 706dd0b6-367c-4950-88fe-7a6c0661c2b9

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.